The Use of Trifluoperazine in Transfusion Dependent DBA (DBA)
Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia
Sponsor: Adrianna Vlachos, MD
Terminated
Supporter terminated study due to slow subject accrual secondary to COVID pandemic limiting travel to research site.
Listed as NCT03966053, this PHASE1/PHASE2 trial focuses on Diamond Blackfan Anemia and Pure Red Cell Aplasia and remains terminated or withdrawn. Sponsored by Adrianna Vlachos, MD, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
▶ Show 6 earlier versions
-
Apr 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2019 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2019 — Oct 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Adrianna Vlachos, MD
For direct contact, visit the study record on ClinicalTrials.gov .